Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders

Michihide Tokuhira, Shuntaro Saito, Katsuya Suzuki, Morihiro Higashi, Shuju Momose, Takayuki Shimizu, Takehiko Mori, Yuta Kimura, Koichi Amano, Shinichiro Okamoto, Tsutomu Takeuchi, Jun Ichi Tamaru, Masahiro Kizaki

Research output: Contribution to journalArticle

Abstract

Methotrexate (MTX) is one of the potent drugs for autoimmune diseases (ADs), especially for rheumatoid arthritis. Recent studies suggest that MTX should be immediately withdrawn when patients with AD develop lymphoproliferative disorder (LPD). However, biopsy cannot be performed for diagnosis because LPD regresses quickly after MTX withdrawal, thus making clinical MTX-LPD (c-MTX-LPD) challenging to diagnose. In this study, among the 28 patients with c-MTX-LPD, seven developed a proven LPD (p-LPD) after suspicious LPD (s-LPD) regression, six of which were Hodgkin lymphoma. Four of seven patients with p-LPD + died, whereas all patients with p-LPD– survived. The clinical manifestations indicative of p-LPD include fever, elevated serum C-reactive protein level, and soluble interleukin-2 receptor level. Anti-AD drugs did not appear to affect the pathogenesis of p-LPD development. P-LPD was not observed after 3 years from the time of s-LPD regression.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Lymphoproliferative Disorders
Methotrexate
Autoimmune Diseases
Interleukin-2 Receptors
Hodgkin Disease
Pharmaceutical Preparations
C-Reactive Protein
Blood Proteins
Rheumatoid Arthritis
Fever
Biopsy

Keywords

  • Clinical
  • lymphoproliferative disorders
  • methotrexate
  • proven
  • rheumatoid arthritis
  • suspicious

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. / Tokuhira, Michihide; Saito, Shuntaro; Suzuki, Katsuya; Higashi, Morihiro; Momose, Shuju; Shimizu, Takayuki; Mori, Takehiko; Kimura, Yuta; Amano, Koichi; Okamoto, Shinichiro; Takeuchi, Tsutomu; Tamaru, Jun Ichi; Kizaki, Masahiro.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Tokuhira, Michihide ; Saito, Shuntaro ; Suzuki, Katsuya ; Higashi, Morihiro ; Momose, Shuju ; Shimizu, Takayuki ; Mori, Takehiko ; Kimura, Yuta ; Amano, Koichi ; Okamoto, Shinichiro ; Takeuchi, Tsutomu ; Tamaru, Jun Ichi ; Kizaki, Masahiro. / Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. In: Leukemia and Lymphoma. 2019.
@article{34bcbe1e8f4c492eabc7baf8ef438762,
title = "Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders",
abstract = "Methotrexate (MTX) is one of the potent drugs for autoimmune diseases (ADs), especially for rheumatoid arthritis. Recent studies suggest that MTX should be immediately withdrawn when patients with AD develop lymphoproliferative disorder (LPD). However, biopsy cannot be performed for diagnosis because LPD regresses quickly after MTX withdrawal, thus making clinical MTX-LPD (c-MTX-LPD) challenging to diagnose. In this study, among the 28 patients with c-MTX-LPD, seven developed a proven LPD (p-LPD) after suspicious LPD (s-LPD) regression, six of which were Hodgkin lymphoma. Four of seven patients with p-LPD + died, whereas all patients with p-LPD– survived. The clinical manifestations indicative of p-LPD include fever, elevated serum C-reactive protein level, and soluble interleukin-2 receptor level. Anti-AD drugs did not appear to affect the pathogenesis of p-LPD development. P-LPD was not observed after 3 years from the time of s-LPD regression.",
keywords = "Clinical, lymphoproliferative disorders, methotrexate, proven, rheumatoid arthritis, suspicious",
author = "Michihide Tokuhira and Shuntaro Saito and Katsuya Suzuki and Morihiro Higashi and Shuju Momose and Takayuki Shimizu and Takehiko Mori and Yuta Kimura and Koichi Amano and Shinichiro Okamoto and Tsutomu Takeuchi and Tamaru, {Jun Ichi} and Masahiro Kizaki",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1585841",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders

AU - Tokuhira, Michihide

AU - Saito, Shuntaro

AU - Suzuki, Katsuya

AU - Higashi, Morihiro

AU - Momose, Shuju

AU - Shimizu, Takayuki

AU - Mori, Takehiko

AU - Kimura, Yuta

AU - Amano, Koichi

AU - Okamoto, Shinichiro

AU - Takeuchi, Tsutomu

AU - Tamaru, Jun Ichi

AU - Kizaki, Masahiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Methotrexate (MTX) is one of the potent drugs for autoimmune diseases (ADs), especially for rheumatoid arthritis. Recent studies suggest that MTX should be immediately withdrawn when patients with AD develop lymphoproliferative disorder (LPD). However, biopsy cannot be performed for diagnosis because LPD regresses quickly after MTX withdrawal, thus making clinical MTX-LPD (c-MTX-LPD) challenging to diagnose. In this study, among the 28 patients with c-MTX-LPD, seven developed a proven LPD (p-LPD) after suspicious LPD (s-LPD) regression, six of which were Hodgkin lymphoma. Four of seven patients with p-LPD + died, whereas all patients with p-LPD– survived. The clinical manifestations indicative of p-LPD include fever, elevated serum C-reactive protein level, and soluble interleukin-2 receptor level. Anti-AD drugs did not appear to affect the pathogenesis of p-LPD development. P-LPD was not observed after 3 years from the time of s-LPD regression.

AB - Methotrexate (MTX) is one of the potent drugs for autoimmune diseases (ADs), especially for rheumatoid arthritis. Recent studies suggest that MTX should be immediately withdrawn when patients with AD develop lymphoproliferative disorder (LPD). However, biopsy cannot be performed for diagnosis because LPD regresses quickly after MTX withdrawal, thus making clinical MTX-LPD (c-MTX-LPD) challenging to diagnose. In this study, among the 28 patients with c-MTX-LPD, seven developed a proven LPD (p-LPD) after suspicious LPD (s-LPD) regression, six of which were Hodgkin lymphoma. Four of seven patients with p-LPD + died, whereas all patients with p-LPD– survived. The clinical manifestations indicative of p-LPD include fever, elevated serum C-reactive protein level, and soluble interleukin-2 receptor level. Anti-AD drugs did not appear to affect the pathogenesis of p-LPD development. P-LPD was not observed after 3 years from the time of s-LPD regression.

KW - Clinical

KW - lymphoproliferative disorders

KW - methotrexate

KW - proven

KW - rheumatoid arthritis

KW - suspicious

UR - http://www.scopus.com/inward/record.url?scp=85063860176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063860176&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1585841

DO - 10.1080/10428194.2019.1585841

M3 - Article

C2 - 30947579

AN - SCOPUS:85063860176

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -